» Articles » PMID: 304012

Serum Half-life and Organ Distribution of Radiolabeled Colony Stimulating Factor in Mice

Overview
Journal Exp Hematol
Specialty Hematology
Date 1977 Nov 1
PMID 304012
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Granulocyte-macrophage colony stimulating factor (GM-CSF) from mouse lung conditioned medium has recently been purified. This GM-CSF was radioiodinated using the chloramine T method, but dimethylsulfoxide was needed to prevent the loss of biological activity during the iodination. 125I-labeled GM-CSF was isolated from the reaction mixture by gel filtration and affinity chromatography with concanavalin A-Sepharose. One hour after intravenous injection of 125I-labeled GM-CSF almost 80% of the radioactivity was still localized in the serum. 125I-labeled GM-CSF was cleared from the blood of C57BL mice with a serum half-life of 7.3 +/- 1.3 hours. Six hours after intravenous injection 125I-GM-CSF appeared to be distributed throughout most of the tissues of C57BL mice. There was no selective concentration of 125I-labeled GM-CSF in the bone marrow, but levels in the kidney were three times higher than expected from the distribution of 125I-labeled mouse serum albumin. 125I detected in the blood 6 hours after injection of 125I-labeled GM-CSF was precipitable with trichloroacetic acid and bound to concanavalin A-Sepharose. 125I detected in the urine was not macromolecular and appeared to result from the degradation of 125I-labeled GM-CSF.

Citing Articles

Immortalized human myoblast cell lines for the delivery of therapeutic proteins using encapsulated cell technology.

Lathuiliere A, Vernet R, Charrier E, Urwyler M, von Rohr O, Belkouch M Mol Ther Methods Clin Dev. 2022; 26:441-458.

PMID: 36092361 PMC: 9418741. DOI: 10.1016/j.omtm.2022.07.017.


Development of an extended half-life GM-CSF fusion protein for Parkinson's disease.

Yeapuri P, Olson K, Lu Y, Abdelmoaty M, Namminga K, Markovic M J Control Release. 2022; 348:951-965.

PMID: 35738463 PMC: 10350880. DOI: 10.1016/j.jconrel.2022.06.024.


The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy.

Zheng X, Wu Y, Bi J, Huang Y, Cheng Y, Li Y Cell Mol Immunol. 2022; 19(2):192-209.

PMID: 35043005 PMC: 8803834. DOI: 10.1038/s41423-021-00786-6.


Albumin fusion with granulocyte-macrophage colony-stimulating factor acts as an immunotherapy against chronic tuberculosis.

Chuang Y, He L, Pinn M, Tsai Y, Cheng M, Farmer E Cell Mol Immunol. 2020; 18(10):2393-2401.

PMID: 32382128 PMC: 8484439. DOI: 10.1038/s41423-020-0439-2.


Drug delivery and tissue engineering to promote wound healing in the immunocompromised host: Current challenges and future directions.

Tatara A, Kontoyiannis D, Mikos A Adv Drug Deliv Rev. 2017; 129:319-329.

PMID: 29221962 PMC: 5988908. DOI: 10.1016/j.addr.2017.12.001.